EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study

Ferdinando D'Amico iD, Luca Massimino, Giulia Palmieri, Arianna Dal Buono, Roberto Gabbiadini, Benedicte Caron, Paula Moreira, Isabel Silva, Maia Bosca-Watts, Tommaso Innocenti, Gabriele Dragoni, Cristina Bezzio und 17 weitere

European Journal of Clinical Investigation · 2024

DOI: 10.1111/eci.14283 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Clinical Investigation, 2024. Verfasst von Ferdinando D'Amico und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Infliximab, Antibodies, Monoclonal, Humanized, Colitis, Ulcerative, Gastrointestinal Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Subcutaneous (SC) formulations of infliximab (IFX) and vedolizumab (VDZ) are approved for the treatment of inflammatory bowel diseases (IBDs). Our aim was to evaluate the effectiveness of switching from intravenous (IV) to SC formulations of IFX and VDZ in IBDs.

Methods

This multicentre, retrospective study collected data of adult patients with Crohn's disease (CD) or ulcerative colitis (UC) switched to SC IFX or VDZ. The primary endpoint was clinical remission at 12 months stratified based on timing of switch. A composite endpoint consisting of therapy discontinuation, reverse‐switch, need for steroids, and drug optimization was evaluated. A multivariate analysis investigated the association between patients' characteristics and outcomes.

Results

Two hundred and thirty‐one patients (59% UC, 53% male, mean age 44 ± 15 years, 68% IFX) from 13 centres were included. The switch occurred at Week 6 in a third of cases (36%). Median time to switch was 13 months. Most patients switched to SC IFX and VDZ were in clinical remission at 3 (87% and 77%), 6 (86% and 83%) and 12 (63% and 60%) months. In the multivariate analysis, there was no difference in clinical remission rate at 12 months; however, patients switched at Week 6 had a higher rate of experiencing any therapeutic changes at 3 (false discovery rate (FDR) = .002), 6 (FDR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabAntibodies, Monoclonal, HumanizedColitis, UlcerativeGastrointestinal AgentsCrohn DiseaseRemission InductionHumansMaleFemaleAdultMiddle AgedRetrospective StudiesInjections, SubcutaneousDrug SubstitutionAdministration, IntravenousTreatment OutcomeInflammatory Bowel Diseases

Stichwörter der Autor:innen

Crohn's disease, disease‐basedUlcerative colitis, disease‐basedinflammatory bowel disease, disease‐based

Substanzen

vedolizumabInfliximabAntibodies, Monoclonal, HumanizedGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy.
  • Experimental Gastroenterology Unit, Division of Immunology, Transplantation and Infectious Disease, IRCCS Ospedale San Raffaele, Milan, Italy.
  • IBD Center, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
  • INSERM, NGERE, University of Lorraine, Nancy, France.
  • INFINY Institute, Nancy University Hospital, Vandœuvre-lès-Nancy, France.

ORCID-Profile: Ferdinando D'Amico

Zitieren

APA

D'Amico, F., Massimino, L., Palmieri, G., Dal Buono, A., Gabbiadini, R., Caron, B., Moreira, P., Silva, I., Bosca-Watts, M., Innocenti, T., Dragoni, G., Bezzio, C., Zilli, A., Furfaro, F., Saibeni, S., Chaparro, M., García, M. J., Michalopoulos, G., Viazis, N., …, & Allocca, M. (2024). An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14283

Vancouver

D'Amico F, Massimino L, Palmieri G, Dal Buono A, Gabbiadini R, Caron B, et al. An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14283

BibTeX
@article{DAmico2024,
  author = {D'Amico, Ferdinando and Massimino, Luca and Palmieri, Giulia and Dal Buono, Arianna and Gabbiadini, Roberto and Caron, Benedicte and Moreira, Paula and Silva, Isabel and Bosca-Watts, Maia and Innocenti, Tommaso and Dragoni, Gabriele and Bezzio, Cristina and Zilli, Alessandra and Furfaro, Federica and Saibeni, Simone and Chaparro, María and García, María José and Michalopoulos, George and Viazis, Nikos and Mantzaris, Gerassimos J and Ellul, Pierre and Gisbert, Javier P and Magro, Fernando and Peyrin-Biroulet, Laurent and Armuzzi, Alessandro and Ungaro, Federica and Danese, Silvio and Fiorino, Gionata and Allocca, Mariangela},
  title = {An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study},
  journal = {European Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1111/eci.14283}
}
Kostenlos starten →